Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria La Fe (17)

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

2021

  1. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891

  2. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

    The Lancet, Vol. 398, Núm. 10295, pp. 131-142

2020

  1. Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer

    European Urology

  2. Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

    Therapeutic Advances in Medical Oncology, Vol. 12

  3. Latest progress in molecular biology and treatment in genitourinary tumours

    Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195

  4. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma

    International Journal of Cancer, Vol. 146, Núm. 5, pp. 1435-1444

2019

  1. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

    European Journal of Cancer, Vol. 116, pp. 158-168

  2. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

    European Urology, Vol. 75, Núm. 3, pp. 368-373

  3. Prorepair-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer

    Journal of Clinical Oncology, Vol. 37, Núm. 6, pp. 490-503

  4. Real-world outcome of 173 metastatic non-clear cell renal cell carcinoma (nccrcc) cases: The experience of the center group for genitourinary tumors

    Kidney Cancer, Vol. 3, Núm. 1, pp. 41-50

  5. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study

    Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789

  6. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

    Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32

2018

  1. Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)

    Breast Cancer Research and Treatment

  2. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

    Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634

2013

  1. Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: Efficacy and safety data according to liver function

    Clinical and Translational Oncology, Vol. 15, Núm. 2, pp. 146-153

2012

  1. Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers

    Journal of Cancer Research and Clinical Oncology, Vol. 138, Núm. 5, pp. 867-875